Roundtable Discussion: Preparing for In Vivo Therapies to Protect Market Position & Adapt Sourcing Strategies for Long-Term Competitiveness

• Examining whether in vivo CAR-T and gene therapy approaches could reduce demand for ex vivo cell manufacturing and donor sourcing infrastructure
• Discussing how the allogeneic cell therapy field should respond to competitive pressure from in vivo modalities to maintain relevance and investment
• Evaluating whether suppliers, CDMOs and technology providers will sustain business models if market demand shifts toward in vivo approaches

Speakers:

Sanjeev Luther

President & Chief Executive Officer

Ernexa Therapeutics